As we have mentioned previously, data on the use of a variety of methods of urine testing in assessment of risk for clinically significant prostate cancer (and therefore the need for a follow-up biopsy) continues to evolve. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: MyProstateScore, risk, test, urine | Leave a comment »
It is becoming very clear that over the next 5 to 10 years we will develop a whole new spectrum of urine-based tests for the assessment of risk for prostate cancer and whether a specific patient will actually need a biopsy and/or other tests to confirm diagnosis. … READ MORE…
Filed under: Diagnosis, Risk | Tagged: future, risk, screening, test, urine | 1 Comment »
So our good friend Howard Wolinsky has just written up his assessment on the evolution of the use of the PSA test in “screening” for prostate cancer in an article on the MedPage Today web site. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, test | 17 Comments »
According to a media release issued on Tuesday this week by miR Scientific, the US Food and Drug Administration (FDA) has issued a Breakthrough Device Designation for the company’s new urine-based test for risk of prostate cancer (the miR Sentinel™ Prostate Test). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: miR Sentinel, risk, test, urine | 5 Comments »
Earlier this year, at the annual Genitourinary Cancer symposium in San Francisco, we were first given information about the potential of three new tests for the diagnosis of prostate cancer: the so-called miR Sentinel tests from miR Scientific. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, exome, miR, sentinel, test, urine | 10 Comments »
A newly published article by Shoag et al. in the New England Journal of Medicine (NEJM) has suggested that the risks associated with “screening” for prostate cancer using the PSA test may not be as high as previously suggested. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: benefit, PSA, risk, screening, test | 4 Comments »
A newly published article in BJU International has described a way to test post-DRE urine samples for the presence of specific types of ribonucleic acid (RNA) and use these data to detect and classify risk levels for more and less aggressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, prognosis, PUR, risk. classification, test, urine | 4 Comments »
Three different molecular tests have been validated as providing useful data that can help a man and his doctors to come to decisions about the management and treatment of localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Decipher, genetic, genomic, molecular, Oncotype, PROLARIS, test | 2 Comments »
As our friend Howard Wolinsky continues his journalistic exploits into the world of prostate cancer, he has (almost inevitably) come across an issue of “conflicts of interest”, … READ MORE …
Filed under: Uncategorized | Tagged: 4Kscore, conflict, interest, phi, test | 1 Comment »
The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active, atenolol, biopsy, genomic, MRI, PI-RADS, predict, prognosis, scan, surveillance, test | 4 Comments »
In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled … READ MORE …
Filed under: Uncategorized | Tagged: DNA, genetic, genomic, germline, test | 2 Comments »
So first the “less good” news … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: OPKO, point of care, PSA, Sangia, test | 6 Comments »
The Prostate Cancer Foundation posted two useful and basic articles on its blog site this December that may be useful resources for men concerned about their risk for or newly diagnosed with prostate cancer or monitoring their PSA over time (for any one of all sorts of possible reasons). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: accuracy, advice, diagnosed, guidance, newly, PSA, test | 4 Comments »
By now, many readers have probably seen news reports coming out of Australia about the “possible medical breakthrough” of a rapid, highly accurate test that can be used to detect cancer anywhere in the body (prostate cancer specifically included). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: cancer, DNA, methylation, Methylscape, test | 2 Comments »
We have recently learned that Medicare will be covering the costs of the Oncotype DX AR-V7 Nucleus Detect™ test for patients with metastatic, castration-resistant prostate cancer (mCRPC) as of December 10, 2018. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: AR-V7, Genomic Health, Oncotype, test | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 